Tobramycin dry-powder inhalation - Novartis
Alternative Names: TBM 100; TIP; TOBI Podhaler; TOBI-TIP; Tobramycin inhalation powder-NovartisLatest Information Update: 26 Apr 2022
At a glance
- Originator Nektar Therapeutics
- Developer Novartis
- Class Aminoglycosides; Anti-infectives; Antibacterials; Antibronchitics; Small molecules
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cystic fibrosis-associated respiratory tract infections
- No development reported Bronchiectasis
Most Recent Events
- 26 Apr 2022 No development reported - Phase-II for Bronchiectasis (Adjunctive treatment, Non-cystic fibrosis-related) in Italy, Spain, Germany, Ireland, United Kingdom, Belgium, France, Netherlands (Inhalation)
- 15 May 2020 Efficacy and adverse events data from a phase II iBest-1 trial in Bronchiectasis presented at the 116th International Conference of the American Thoracic Society (ATS-2020)
- 20 Mar 2019 Novartis completes a phase II trial in Bronchiectasis (Adjunctive treatment, Non-cystic fibrosis related) in Italy, Spain, Germany, Ireland, United Kingdom, Belgium, Netherlands, France (Inhalation) (NCT02712983) (EudraCT2015-003040-39)